[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,54,89,110,130,159,189,219,263,290,319,349,364,394,419,441,468,502,522,545,563,593,618,646,678],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":4,"leadSponsor":50,"locationsCount":53},"100133849","the-natural-history-of-severe-viral-infections-and-characterization-of-immune-defects-in-patients-without-known-immunocompromise-100133849",false,"NCT01011712","The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise","The Natural History of Severe Viral Infections and Characterization of Immune Defects","* INCLUSION CRITERIA:\n\n(Participants)\n\nParticipants must meet all the following inclusion criteria in order to participate in this study:\n\n1. Children or adults (regardless of age) with a definitively diagnosed severe or unusual viral infection, including but not limited to infections caused by herpesviruses (HSV-1, HSV-2, CMV, EBV, VZV, HHV-6, HHV-7, HHV-8), human papillomavirus (e.g., severe recalcitrant warts), adenovirus, calicivirus (e.g. norovirus), polyomavirus (such as JC virus and BK virus), or influenza virus. Viral infections that would be considered opportunistic-like , such as herpesvirus esophagitis, herpesvirus encephalitis, CMV colitis, or progressive multifocal leukoencephalopathy (caused by the JC polyoma virus) will be of particular interest in this protocol.\n\n   OR\n\n   Children or adults with a well-documented prior, severe, persistent, or treatment-refractory viral infection(s), who have clinically recovered from the viral infection.\n2. Ongoing care by a referring physician.\n3. Willingness to allow storage of blood and tissue samples for future analyses.\n\n(Relatives)\n\nRelatives (2 years or above) may be recruited and enrolled to improve interpretation of genetic results, to expand the phenotype of the suspected or confirmed inborn error of immunity in the proband with severe viral infection, and to understand the co-factors in affected and\u002For unaffected family members that may influence variable expressivity and penetrance of viral infections in inborn errors of immunity.\n\n1. Males and females will be accepted.\n2. Relatives may either be healthy or have features concerning for an inborn error of immunity including, but not limited to, autoimmunity, severe atopy, other forms of immune-dysregulation, or severe or unusual infections. While the enrolled proband must have a current or prior severe or unusual viral infection, family members who are suspected to have an inborn error of immunity do not need to have a history of severe or unusual viral infection in the presence of other features suspicious for inborn errors of immunity.\n3. Adult relatives or the guardians of minor relatives must be willing and capable of providing informed consent after review of protocol procedures that are described in the consent form with an appropriate study team member.\n4. Participating relatives agree to have blood stored for future studies of the immune system.\n\nEXCLUSION CRITERIA:\n\nParticipants meeting any of the following exclusion criteria at baseline will be excluded from study participation:\n\n1. Patients with previously diagnosed conditions associated with acquired or iatrogenic immunodeficiency and\u002For immunosuppresion (e.g., a history of HIV infection, a positive test for HIV, chemotherapy or high dose glucocorticoids). Patients on immunosuppression and\u002For immunomodulatory therapy for the treatment of conditions that may be attributable to an underlying inborn error of immunity may be included in the study at the discretion of the PI or their designee.\n2. Women who are pregnant.\n3. Any condition or major comorbidity that the study investigators believe will compromise the patient's ability to comply with the requirements of the study.","ALL","2 Years","100 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses. Usually, these illnesses last only few days or, at most, a few weeks. Some virus infections like influenza are cleared from the body, and others such as the chicken pox virus remain in the body in an inactive state. However, some people may become quite ill when they are infected with a particular virus, possibly because part of their immune system does not respond properly to fight the virus.\n* Researchers have discovered some reasons why a person may not be able to clear an infection caused by a virus. Some persons have changes in the genes that involve the immune system that result in the inability to properly control infection with a particular virus. Identifying changes in genes that involve the immune system should help scientists better understand how the immune system works to protect people from infection and may help develop new therapies.\n\nObjectives:\n\n* To study possible immune defects that may be linked to a particular severe viral infection.\n* To determine if identified immune defects are genetic in origin.\n\nEligibility:\n\n* Individuals of any age who have or have had a diagnosis of a virus infection that physicians consider to be unusually severe, prolonged, or difficult to treat.\n* Relatives of the participants with a severe viral infection may also participate in the study. We will use their blood and\u002For skin specimens to try to determine if identified immune defects are hereditary.\n\nDesign:\n\n* Prior to the study, the participant's doctor will give researchers the details of the infection, along with medical records for review. Eligible participants will be invited to the NIH Clinical Center for a full evaluation as an outpatient or inpatient.\n* At the Clinical Center, participants will be treated with the best available therapy for the particular viral infection, and researchers will monitor how the infection responds to the treatment.\n* Researchers will take intermittent blood samples and conduct other tests (such as skin biopsies) to evaluate the immune system. - During and after the illness, researchers will conduct follow-up visits to determine the course of infection and response to therapy.",[26,27,28,29,30],"EBV","HSV","VZV","HPV","CMV",[32,33,34,35,36,37,38,39,40,41,42],"Genetics","Virus","Defense","Immunity","Immunodeficiency","Natural History","Respiratory Viruses","Herpesvirus","Cytomegalovirus","Human Papillomavirus","Adenovirus","RECRUITING","2026-08-21",{"date":46,"type":47},"2026-08-24","ACTUAL",{"date":49,"type":47},"2009-10-01",{"name":51,"class":52},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100615711","my-self-sampling-for-hpv-awareness-results-and-empowerment-100615711","NCT07296159","My Self-Sampling for HPV Awareness, Results, and Empowerment","A Technology-enhanced and Multilevel Approach to Promote Cervical Cancer Prevention Among Women Living With HIV","MySHARE+","Aim 1 Provider Prompt: Healthcare and\u002For service provider to women living with HIV\n\nAim 2 RCT Pilot\n\nInclusion Criteria:\n\n* Have an HIV diagnosis\n* Are between 30 to 65 years old\n* Have not had a Pap smear within the last 12 months or more.\n\nExclusion Criteria:\n\n* Have had a history of hysterectomy or invasive cervical cancer\n* Are currently pregnant or were pregnant in the past 3 months\n* Are currently participating or enrolled in similar studies within the past year.",true,"30 Years","65 Years",{"count":66,"type":22},130,"INTERVENTIONAL",[69],"NA","The overall objective of this study is to conduct formative research and pilot test the provider-level and patient-level components of the My Self-Sampling for HPV Awareness, Results, and Empowerment (MySHARE+) intervention. MySHARE+ aims to harness the power of technology and apply a multilevel approach to promote the adoption of cervical cancer screening (HPV self-sampling; Pap triage adherence) among under\u002Fnever-screened women living with HIV (WLH). The specific aims are to 1) identify facilitators and barriers to implementing a healthcare provider prompt in a primary care setting and 2) conduct a pilot randomized controlled trial (RCT) to examine the feasibility, acceptability, and preliminary efficacy of a mHealth educational intervention in promoting cervical cancer awareness and HPV self-sampling among WLH.\n\nUnder aim 1: Providers of healthcare and\u002For social services to WLH will complete an online survey to identify barriers to implementing a healthcare provider prompt in a primary care setting and participate in semi-structured interviews to provide feedback on drafted prompts. Prompts will be piloted at one local clinic to improve patient-provider communication about cervical cancer screening, followed with semi-structured interviews with providers involved.\n\nUnder aim 2: Participants will be enrolled in a text messaging intervention and sent an HPV self-sampling test kit to return via mail. Participants in the intervention group will receive the full mHealth intervention while the control group will receive more generic text messages and reminders over the course of the study.",[72,73,29],"Cervical Cancer","Cervical Cancer Screening",[75,29,76,77],"Cervical cancer","HPV self-sampling","mHealth","NOT_YET_RECRUITING","2026-08-14",{"date":81,"type":47},"2026-08-18",{"date":83,"type":22},"2027-01-01",{"date":85,"type":22},"2029-08-31",{"name":87,"class":88},"Daisy Le","OTHER",{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":67,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100524526","prevencin-en-sus-manos-feasibility-of-a-novel-community-based-strategy-to-improve-access-to-cervical-cancer-screening-100524526","NCT06109870","Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent form\n* Currently resident in RGV or other low-resource community in Texas\n* Stated willingness to comply with all study procedures\n* Females; Age ≥25 years\n* Have no history of hysterectomy with removal of the cervix\n* Have no history of cervical cancer or high-grade dysplasia\n* Have not had a Pap test in the past 3.5 years or Pap\u002FHPV co-test in the past 5.5 years.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Unable to communicate in English or Spanish\n* Lack valid telephone contact information\n* Report being currently pregnant.","18 Years",{"count":97,"type":22},920,[69],"Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.",[29],"2026-08-13",{"date":79,"type":47},{"date":104,"type":47},"2023-10-30",{"date":106,"type":22},"2030-08-31",{"name":108,"class":88},"M.D. Anderson Cancer Center",2,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":62,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":67,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":53},"100504457","msaada-a-mobile-health-tool-100504457","NCT05848557","mSaada: A Mobile Health Tool","mSaada: A Mobile Health Tool to Improve Cervical Cancer Screening in Western Kenya","R21\n\nAim 1 Community health volunteers (CHVs), facility providers and supervisors, Ministry of Health officials\n\nInclusion Criteria:\n\n* 18 years or older\n* be employed by a government clinic\n* be working in cervical cancer screening\n\nExclusion Criteria:\n\n* Does not understand the study purpose and details\n* Is not willing to provide informed consent\n\nWomen\n\nInclusion Criteria:\n\n\\- between 30 and 65 years old\n\nExclusion Criteria:\n\n* Does not understand the study purpose and details\n* Is not willing to provide informed consent\n\nAim 2 Community health volunteers (CHVs)\n\nInclusion Criteria:\n\n* 18 years or older\n* be employed by a government clinic\n* be working in cervical cancer screening\n\nExclusion Criteria:\n\n* Does not understand the study purpose and details\n* Is not willing to provide informed consent\n\nWomen\n\nInclusion Criteria:\n\n* between 30 and 65 years old\n* intact cervix and uterus\n* able to provide informed consent.\n\nExclusion Criteria:\n\n* Does not understand the study purpose and details\n* Is not willing to provide informed consent\n\nR33\n\nWomen (knowledge and risk perception surveys) We plan to enroll approximately 600 women (50 per health facility) to complete a survey about cervical cancer and HPV knowledge, risk perception and screening awareness, acceptability and self-efficacy.\\\\\n\nEligibility criteria for women participants include:\n\n* Reside within Siaya County, in one of the study communities\n* Eligible for cervical cancer screening per the Kenya Ministry of Health guidelines and\n* Ability to provide informed consent.\n\nCHPs in both arms will be asked to complete a survey about their self-efficacy, knowledge of HPV and cervical cancer, and the usability of the mSaada app (CHPs in the intervention arm only).\n\nInclusion:\n\n* CHV participants must be employed by government clinics in Siaya County, and\n* be able to provide informed consent.\n\nExclusion:\n\n* Does not understand the study purpose and details\n* Is not willing to sign an informed consent",{"count":118,"type":22},6000,[69],"In the R21 phase of this project, investigators will: (1) work with key stakeholders and local and international developers to finalize the mSaada platform, building on the existing prototype to add patient and specimen tracking functionality; and (2) carry out a pilot to identify the patient, provider and health system factors necessary to design a trial to evaluate mSaada effectiveness in assisting community health volunteer-led home-based HPV screening, and implementation factors. Investigators will carry out a six-month pilot of mSaada with community units in two health facilities providing HPV-based screening, and use performance metrics including system usage rates, workflow observations and qualitative data to guide the planning of a to determine effectiveness.\n\nIn the R33 phase of the project, investigators plan to: (1) conduct an 18-month c-RCT across 12 health facilities to determine the impact of mSaada on cervical cancer screening uptake, treatment acquisition and cervical cancer knowledge levels among women in the community; and (2) measure the requisite implementation factors for mSaada effectiveness, sustainability, and scale-up. The rigorous study design will allow us to determine the clinical impact of mSaada, ensure the local and regional infrastructure has the capacity necessary for sustainability and develop strategies for widespread implementation and scale-up. Collaboration with key stakeholders from the Kenya Ministry of Health will facilitate the development of a long-term sustainability plan as the country moves toward HPV-based cervical cancer screening. Investigators anticipate the mSaada platform will play a pivotal role in facilitating the introduction of HPV-based screening programs that can reach women in settings with limited health care infrastructure.",[72,29,77],"2026-08-11",{"date":101,"type":47},{"date":125,"type":47},"2024-02-19",{"date":127,"type":22},"2027-06-30",{"name":129,"class":88},"Duke University",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":62,"sex":138,"minAge":139,"maxAge":64,"enrollmentInfo":140,"targetDuration":4,"studyType":67,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":158},"100651238","comparative-self-collection-for-cervical-cancer-screening-pivotal-study-100651238","NCT07758140","Comparative Self-collection for Cervical Cancer Screening Pivotal Study","MIA-COMP Pivotal Study: COMParative Self-Collection for Cervical Cancer Screening","MIA-COMP","Inclusion Criteria:\n\nGroup 1: General Population Group\n\n1. Participants are 25 to 65 years of age and willing to provide informed consent.\n2. Participants have an intact cervix.\n\nGroup 2: Enriched Population Group\n\n1. Participants are 25 to 65 years of age and willing to provide informed consent.\n2. Participants have an intact cervix.\n3. One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and\u002For presenting for colposcopy\u002FLEEP\u002Fexcisional intervention.\n\nExclusion Criteria:\n\nApply to all groups:\n\n1. Impaired decision-making capacity or inability to provide informed consent.\n2. History of partial or total hysterectomy, including removal of the cervix.\n3. Cervical tissue alteration or surgery within 5 months prior (conization, LEEP, laser ablation, or cryotherapy).\n4. Current pregnancy (based on self-reporting).\n5. Active menstruation at time of specimen collection.\n6. Vaginal bleeding within 48 hours.\n7. Have had sex or used tampons, creams, or other vaginal products in the last 48 hours.\n8. Participation in another clinical study that, in the investigator's opinion, would interfere with the results of this study.\n9. Any medical reason that, in the investigator's opinion, would disqualify the participant for a routine pelvic exam with cervical sample collection.","FEMALE","25 Years",{"count":141,"type":22},260,[69],"To evaluate whether individuals drawn from the intended use population can successfully interpret and follow the IFU for the Mia by XytoTest self-collection device and perform a vaginal sample collection yielding sufficient cellular material for primary hrHPV screening.\n\nTo assess the clinical performance of Mia self-collected vaginal specimens by evaluating agreement with paired clinician-collected cervical specimens for the detection of high-risk HPV, when both specimen types are analyzed using the cobas HPV Test (Roche Molecular Systems). Residual samples may be used to determine adequacy for additional assays that require vaginal and\u002For cervical specimens (such as mRNA E6 and E7 Biomarker Test, dual stain cytology).",[29,145],"HPV - Anogenital Human Papilloma Virus Infection",[147,148],"hrHPV","cobas HPV test","2026-08-06",{"date":122,"type":47},{"date":152,"type":47},"2026-07-09",{"date":154,"type":22},"2026-09",{"name":156,"class":157},"Mel Mont Medical","INDUSTRY",11,{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":62,"sex":138,"minAge":139,"maxAge":64,"enrollmentInfo":166,"targetDuration":4,"studyType":67,"phases":168,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":53},"100618785","popsci-chw4cervixhealth-100618785","NCT07336134","PopSci CHW4CervixHealth","Uptake of HPV Self-sampling in Underserved Minority Women Using a Community Health Worker Model: Comparison of Evalyn Brush and Copan Floqswab","Inclusion Criteria:\n\nPhase I:\n\n* Women aged 25-65 years\n* Scheduled for a Pap smear test appointment at Jefferson OBGYN Center City location\n* Willing and able to provide informed consent for participation in the study\n* Agree to perform an HPV self-collection collection procedure during the same visit\n* Have not undergone a hysterectomy (intact cervix required)\n\nPhase II:\n\nThis intervention targets under-screened minority individuals who must meet all the following inclusion criteria to be eligible to participate in the study:\n\n* Women aged 25-65 years\n* Who has not had a Pap smear in the past three to five years based on age of prior screening and type of screening. If under the age of 30, in the past 3 years and if over the age of 30, in the past 5 years. Participant will self-report normal pap smear and date.\n* Self-identify as Hispanic, Black\u002FAfrican or Black Caribbean, Chinese, Korean, or Vietnamese\n* Competent to give consent and provide signed and dated informed consent form in their preferred language.\n\nExclusion Criteria:\n\nPhase I:\n\n* Current pregnancy (self-reported or confirmed)\n* Previous participation in an HPV self-collection study within the past 12 months\n* Presence of visible vaginal or cervical infection or symptoms suggestive of a current genital tract infection\n* Inability to comply with study procedures or follow instructions (e.g., due to language barriers or cognitive impairments)\n\nPhase II:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Have a history of hysterectomy, cervical cancer\n* Self-report participation in a cervical cancer screening or other prevention study\n* Pregnant (self-reported)\n* Inability to provide informed consent",{"count":167,"type":22},120,[69],"Phase I: Validating self-collection kit by comparing their results with clinical Pap smear results in a cohort of 20 patients.\n\nPhase II: Evaluate the feasibility and acceptability of the CHW4CervicalHealth: Use of a self-collection kit to improve cervical health screening intervention aimed to promote HPV self-collection uptake among screening-eligible and under-screened ethnic minority women in the community.",[72,171,172,173],"Hpv","Human Papilloma Virus","HPV Infection",[175,176,177,178,179,180,181],"Copan FLOQswab","Evalyn® Brush","HPV self-collection","self-collection","community health workers","underscreened women","concordance",{"date":122,"type":47},{"date":184,"type":47},"2025-10-22",{"date":186,"type":22},"2026-10-01",{"name":188,"class":88},"Thomas Jefferson University",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":62,"sex":17,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":67,"phases":199,"briefSummary":200,"conditions":201,"keywords":206,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":109},"100649216","national-rapid-tlc-testing-and-linkage-to-care-100649216","NCT07730801","National Rapid TLC: Testing and Linkage to Care","Rapid Testing and Linkage to Care for Underserved and Undiagnosed Populations at Risk of HIV and STBBIs or Living With HIV and STBBIs Across Canada Using the GeneXpert System","Inclusion Criteria:\n\n* Individuals accessing STBBI testing at specific locations who are ≥ 16 years of age\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Unable to provide signed informed consent (e.g., intoxicated)\n* In the opinion of the site PI \u002Fstudy operator, the participant is unable to complete the study elements.\n* Participants who have previously enrolled in the study.","16 Years",{"count":198,"type":22},2500,[69],"The goal of this cross-sectional study is to learn if the GeneXpert system is a practical system for HIV and STBBI testing in community-based organizations and health clinics. The study involves a clinical trial to learn if the HIV-1 Qual XC test works to identify HIV in near-patient settings. The main questions it aims to answer are to create a near-patient testing model for testing and treating patients in a single visit, and to learn if the HIV-1 Qual XC test works to accurately detect HIV in patients. Patients who come to study sites to ask for HIV or STBBI testing will be given the option to participate in the study. Those who agree with provide samples for the tests of their choice and answer survey questions before and after their tests are completed. Those who participate in the clinical trial will have a blood sample sent to provincial labs to compare the results to the HIV -1 Qual XC test. Follow-up visits will be done at 1,3 and 6 months to see if patients completed treatment and\u002For remained connected to care.",[202,203,204,205,29],"HIV","Chlamydia","Gonorrhea","HCV",[207,208,209],"device trial","Canada","GeneXpert","2026-07-27",{"date":212,"type":47},"2026-07-28",{"date":214,"type":22},"2026-08-01",{"date":216,"type":22},"2028-03",{"name":218,"class":88},"Unity Health Toronto",{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":62,"sex":138,"minAge":139,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":67,"phases":228,"briefSummary":229,"conditions":230,"keywords":239,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100614592","evaluation-of-the-q-pad-hrhpv-test-system-for-identifying-precancer-100614592","NCT07281599","Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer","EQUIP","Inclusion Criteria:\n\n* You are 25 years old or older and have an intact cervix.\n* You were referred for a colposcopy after an abnormal Pap or HPV screen.\n* Your periods come regularly-about every 21-35 days.\n* You own a smartphone, have an email address, and can read the Qvin app instructions in English.\n* You are willing to sign the consent form (electronically).\n* You agree to use a condom for any vaginal intercourse or shared penetrative toy use from Q-Pad collection until the colposcopy visit if engaging with a new sexual partner during this period.\n\nExclusion Criteria:\n\n* You are pregnant or think you might be.\n* You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).\n* You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.\n* You have already joined this study or are in another cervical-screening \u002F HPV study right now.",{"count":227,"type":22},450,[69],"The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing.\n\nThe same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.",[173,231,232,73,233,234,29,235,236,237,238],"HPV 16 Infection","High Risk HPV","Cervical Cancer Cin Grade","Cervical Cancer (Early Detection)","HPV (Human Papillomavirus)-Associated","HPV DNA","HPV Infections","Screening Test",[240,241,242,243,244,245,246,247,248,249,29,250,251,252],"Q-Pad","Self-sampling","Self-collection","self-collect","cervical cancer screening","menstural blood","Sexually Transmitted Diseases, Viral","Sexually Transmitted Diseases","Genital Diseases","Papillomavirus Infections","high risk HPV","pap smear","at-home collection","2026-07-22",{"date":255,"type":47},"2026-07-24",{"date":257,"type":47},"2025-12-01",{"date":259,"type":22},"2027-03",{"name":261,"class":157},"Qurasense",3,{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":62,"sex":17,"minAge":270,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":67,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":53},"100631238","digital-interventions-to-increase-hpv-vaccination-intentions-among-nigerian-caregivers-100631238","NCT07498075","Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers","A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers","Inclusion Criteria:\n\n* Parent or primary caregiver of at least one girl aged 9-14 years\n* Parent states \"no\" or \"unsure\" to question asking if eligible daughter has received any doses of the HPV vaccine\n* Provides informed consent to participate\n\nExclusion Criteria:\n\n* Parent or caregiver of a girl who has already received one or more doses of the HPV vaccine\n* Does not meet age eligibility criteria for an eligible daughter\n* Fails Attention Checks","27 Years",{"count":272,"type":22},3340,[69],"This study evaluates whether different types of digital health communication can increase parents' intention to vaccinate their daughters against human papillomavirus (HPV) in Nigeria. HPV vaccination is recommended for girls aged 9-14 years and helps prevent cervical cancer, yet vaccination rates remain low.\n\nParents of eligible, unvaccinated girls will be randomly assigned to receive one of several types of digital content delivered online. These include: (1) a short chatbot conversation based on motivational interviewing principles, (2) an interactive game designed to help parents recognize and resist common forms of vaccine misinformation, (3) a set of short edutainment videos about HPV vaccination, (4) standard informational infographics about HPV vaccination from a national public health agency, or (5) unrelated health content about menstruation.\n\nThe main outcome is parents' self-reported intention to vaccinate their daughter against HPV, measured immediately and one week after exposure to the assigned content. Additional outcomes include HPV-related knowledge, perceptions of vaccine safety, willingness to recommend the vaccine to others, and self-reported vaccine uptake at 1-week and 6 month follow-up. The results will help inform scalable communication strategies to improve HPV vaccination uptake in low- and middle-income settings.",[29,276],"HPV Vaccine",[29,276,278,279,280],"Chatbots","Misinformation","Pre-Bunking","2026-07-15",{"date":283,"type":47},"2026-07-16",{"date":285,"type":47},"2026-05-07",{"date":287,"type":22},"2026-12-31",{"name":289,"class":88},"University of Pennsylvania",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":138,"minAge":139,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":67,"phases":300,"briefSummary":301,"conditions":302,"keywords":307,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":53},"100591342","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-papillex-on-abnormal-cervical-cells-caused-by-hpv-100591342","NCT06979180","A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.","A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV","Inclusion Criteria:\n\n1. Females between 25 and 55 years of age\n2. Females not of child-bearing potential, defined as those who have undergone a permanent sterilization procedure (e.g. hysterectomy, bilateral oophorectomy or bilateral tubal occlusion) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), hormone implant (Norplant System) or intrauterine hormone-releasing system\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomized partner, provided that partner is the sole sexual partner and that the vasectomised partner has received medical assessment of the surgical success\n   * Abstinence\n3. Histologically confirmed CIN1+ (as per standard of care) with concordant hrHPV positivity at that time, and current abnormal cytology and hrHPV positivity at screening; interval between historical diagnosis and screening must be \\>6 months OR documented abnormal cytology (LSIL or worse) plus hrHPV positive \\>6 months prior, and current abnormal cytology with hrHPV positivity at screening\n4. Willing to provide copies of histology and\u002For cytology reports for eligibility confirmation\n5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n6. Willingness to avoid magnetic resonance imaging, computed tomography, X-ray, or other procedures with contrast media injection for 48 hr prior to study visits assessing micronutrient status\n7. Willingness and ability to complete questionnaires and diaries associated with the study, and to complete all clinic visits and assessments\n8. Provided voluntary, written, informed consent to participate in the study\n9. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Women who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance preventing consumption of investigational product or placebo ingredients\n3. Currently undergoing treatment for CIN, are indicated for treatment during the study period, have received treatment (e.g., conization or loop electrosurgical excision procedure) within the last five years, or have active CIN 3\n4. Concurrent uterine pathologies\n5. History of hysterectomy or destructive therapy of the cervix\n6. Cervical cancer\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)\n10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n11. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n15. Individuals with an autoimmune disease or are immune compromised\n16. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n17. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n18. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n19. Alcohol or drug abuse within the last 12 months\n20. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n21. Clinically significant abnormal laboratory results at screening as assessed by the QI\n22. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n23. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n24. Individuals who are cognitively impaired and\u002For who are unable to give informed consent\n25. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","55 Years",{"count":299,"type":22},60,[69],"The goal of this clinical trial is to investigate the safety and efficacy of Papillex® on the regression of abnormal cervical cells caused by HPV in women with a cervical intraepithelial neoplasia (CIN) 1 or 2 diagnosis. The main question it aims to answer is:\n\nIs there a difference in the proportion of participants with a regression in CIN based on histology or cytology from baseline at day 180 between Papillex® and placebo?\n\nParticipants will be asked to consume Papillex® or placebo for 180 days, complete questionnaires, a PAP smear, HPV test, and colonoscopy (where applicable).",[303,304,305,29,306],"CIN - Cervical Intraepithelial Neoplasia","CIN 1","CIN 2","Cervical Cells",[308,29,309],"Cervical intraepithelial neoplasia","Papillex","2026-07-06",{"date":312,"type":47},"2026-07-08",{"date":314,"type":47},"2026-03-01",{"date":316,"type":22},"2026-12",{"name":318,"class":157},"Papillex Inc.",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":138,"minAge":139,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":67,"phases":329,"briefSummary":330,"conditions":331,"keywords":335,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":53},"100643388","feasibility-study-comparing-one-vs-two-probes-for-thermal-ablation-among-cervical-cancer-screen-positive-women-living-with-hiv-in-c1001p-cs7-zimbabwe-100643388","NCT07645352","Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS7 Zimbabwe","Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV","Inclusion Criteria:\n\n1. 25-49 years old\n2. Living with HIV\n\nInclusion criteria specific to the feasibility study\n\n1. Intact cervix\n2. Willing to return to facility at 6 months\n3. Willing and able to provide informed consent\n4. Positive hrHPV or VIA test within 3 months of enrollment\n5. Type 1 transformation zone (TZ1)\n6. Thermal ablation eligible\n\nExclusion Criteria:\n\n1. Screened for cervical cancer outside of study in last 6 months\n2. Currently pregnant or less than 6 weeks postpartum\n3. Prior diagnosis of cervical cancer\n4. A history of treatment for cervical precancer\n5. Total hysterectomy\n6. Currently receiving treatment for any cancer\n7. Individual has a condition that the Clinical Site PI believes will interfere with or affect the conduct, results, or completion of the clinical study\n8. Individual has a condition that the Clinical Site PI considers creates an unacceptable risk to the individual if enrolled","49 Years",{"count":328,"type":22},300,[69],"Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. While thermal ablation (TA) is a WHO- recommended treatment for cervical precancerous lesions, its efficacy can be suboptimal in WLWH. We will also conduct a feasibility treatment cohort study of up to 300 Zimbabwean WLWH to provide evidence for a larger treatment effectiveness study. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings and to contribute towards achieving the 90-70-90 goals of the World Health Organization's (WHO) strategy for accelerated elimination of cervical cancer as a public health problem by 2030.",[332,29,333,334],"HIV (Human Immunodeficiency Virus)","Cervical Precancer","Cervical Neoplasia",[202,336,337,338,339],"Cervical cancer screening","Treatment of Cervical Precancer","Thermal ablation","Human papillomavirus","2026-06-09",{"date":342,"type":47},"2026-06-12",{"date":344,"type":22},"2026-06",{"date":346,"type":22},"2027-05-31",{"name":348,"class":88},"Fred Hutchinson Cancer Center",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":138,"minAge":139,"maxAge":326,"enrollmentInfo":354,"targetDuration":4,"studyType":67,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":362,"leadSponsor":363,"locationsCount":53},"100642783","feasibility-study-comparing-one-vs-two-probes-for-thermal-ablation-among-cervical-cancer-screen-positive-wlwh-in-c1001p-cs9-south-africa-100642783","NCT07645378","Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South Africa",{"count":355,"type":22},200,[69],"Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030.",[332,29,333,334],[202,336,337,338,339],{"date":342,"type":47},{"date":344,"type":22},{"date":346,"type":22},{"name":348,"class":88},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":62,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":67,"phases":374,"briefSummary":375,"conditions":376,"keywords":380,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":4},"100643606","addressing-hpv-vaccine-hesitancy-by-co-designing-a-digital-health-intervention-100643606","NCT07632963","Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention","HPV-Kompassen: a Mixed-Methods Single-Arm Cluster Feasibility Study of a Co-Designed Web-Based Intervention To Strengthen HPV Vaccine Confidence and Uptake in Stockholm, Sweden","HPV-END-IT","We will aim to recruit 6-8 compulsory schools in Stockholm County to serve as clusters.\n\nAll Year 5 pupils and their caregivers in the study schools are invited.\n\nInclusion Criteria:\n\n* The school provides education to pupils in school year 5 and is scheduled to be open throughout the pilot trial period\n* The school is located in an area with HPV vaccine uptake \\\u003C85.2% (the Stockholm regional average)\n* The head principal and school nurse both consent to participate\n* The school has the capacity to implement the intervention\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria",{"count":373,"type":22},100,[69],"This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.\n\nResearchers will give Year 5 pupils (aged 11-12) and their parents or caregivers access to the platform. It provides clear, trusted information about the HPV vaccine for young people, parents, and school nurses. The aim is to make the vaccine easier to understand and to help answer any questions or concerns.\n\nAfter using the platform, participants will be asked to share their thoughts.",[29,377,378,379],"Vaccine Acceptance","Vaccine Decision Making","HPV Vaccination",[381,382,383,384],"Human papilloma virus","HPV vaccine","Vaccine uptake","Vaccine confidence","2026-06-02",{"date":387,"type":47},"2026-06-08",{"date":389,"type":22},"2026-08",{"date":391,"type":22},"2027-06",{"name":393,"class":88},"Karolinska Institutet",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":62,"sex":138,"minAge":95,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":67,"phases":403,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":4},"100640905","effect-of-web-based-education-on-attitudes-and-beliefs-about-hpv-testing-100640905","NCT07620795","Effect of Web-Based Education on Attitudes and Beliefs About HPV Testing","THE EFFECT OF WEB-BASED EDUCATION GIVEN TO WOMEN ON THEIR ATTITUDES AND BELIEFS ABOUT HPV TESTING","Inclusion Criteria:\n\n* Having no prior clinical diagnosis of cervical cancer\n* Being between 18 and 60 years of age\n* Having active access to the internet\n* Being literate at a level sufficient to read and understand the questionnaire forms\n* Being capable of effectively navigating and using a web browser\n* Being registered as a patient at Sakarya Akyazı No. 3 Family Health Center\n* Volunteering to participate in the study and providing informed consent\n\nExclusion Criteria:\n\n* Withdrawing from the study voluntarily at any stage\n* Failing to watch the mandatory educational videos on the platform\n* Submitting incomplete or incorrect responses to the data collection tools\n* Lacking active internet access or proper web browser usage skills\n\nCriteria for Study Discontinuation \u002F Drop-out:\n\n* Participant's request to withdraw from the study\n* Failure to respond to or complete the data collection tools\n* Not using or logging into the web application for more than 2 consecutive weeks during the study period","60 Years",{"count":167,"type":22},[69],"Cervical cancer is a highly preventable public health issue that significantly impacts women's quality of life. Although effective screening programs such as Human Papilloma Virus (HPV) testing and Pap-smears are widely available, women's participation in these early detection services often remains limited. The primary barriers to screening attendance include insufficient education, lack of information, negative beliefs, psychosocial or cultural factors, and misconceptions regarding gynecological examinations. To improve screening uptake, health interventions must focus not only on increasing knowledge but also on promoting correct beliefs and positive attitudes toward testing.\n\nWeb-based health education serves as an effective method to overcome barriers such as cost, transportation difficulties, and geographical limitations, allowing wider access to healthcare guidance. This study aims to evaluate the effects of a specialized web-based educational intervention on women's attitudes and beliefs regarding the HPV test. The research is designed as a randomized controlled trial with a pre-test and post-test design. Participants will be assigned to either an intervention group or a control group. The intervention group will receive structured health education through a dedicated web platform, while the control group will receive routine standard follow-up. Data will be gathered using a specific attitude and belief scale before and after the application to measure the intervention's impact.",[72,29],[407,408,409,410],"HPV Testing","Health Education","Web-based learning","Attitudes and Beliefs","2026-05-27",{"date":385,"type":47},{"date":414,"type":22},"2026-07-01",{"date":416,"type":22},"2026-09-01",{"name":418,"class":88},"Sakarya University",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":62,"sex":17,"minAge":425,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":67,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":53},"100545300","stand-up-2-hpv-standing-orders-to-improve-hpv-vaccination-100545300","NCT06380114","Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination","Inclusion Criteria:\n\n* active patient in AHP practice\n\nExclusion Criteria:\n\n* patient belonging to a practice with \\>80% UTD baseline HPV vaccination rate for ages 13-17\n* patient belonging to a practice with \\\u003C20 11-12 year-olds eligible for an HPV dose","9 Years","17 Years",{"count":428,"type":22},16000,[69],"Each year in the U.S., ≥20,000 women and 14,000 men are affected by HPV-related cancers, including cervical and oropharyngeal cancer. However, in 2020, only 59% of U.S. adolescents aged 13-17 were up-to-date for HPV vaccination, and rates for 11-12 year olds, the primary target age group for HPV vaccination (when the immune reaction is better and before exposure to HPV infection), are even lower. Standing orders (written protocols that authorize designated members of the healthcare team to vaccinate without first obtaining a patient-specific physician order) have been shown to work in inpatient settings and for adults, but have not been evaluated for HPV vaccine, which some parents consider controversial. Also, the ways in which organizational readiness for change (resources, motivation, staff attributes, leadership support and culture) moderate the effect of standing orders has not been studied. A physician's recommendation is correlated with HPV vaccine acceptance, and the investigators have developed a successful online, interactive, communication education program that will be adapted to train nurses and staff in addition to physicians. The investigators propose testing standing orders for HPV vaccine in an Accountable Care Organization (ACO) in Western New York, and assessing which provider and practice factors moderate the effect of standing orders. Advantages of this setting include a diverse group of rural, urban and suburban practices, and the ACO provides data infrastructure and analytics that allow practices to evaluate vaccination rates in real time.\n\nUsing a 2-arm cluster randomized trial (n=40 practices), the investigators will assess the effectiveness of standing orders (SO) + HPV communication education (intervention arm) relative to HPV communication education alone (control arm) on HPV vaccination for 9-17 year-olds.",[171],"2026-05-26",{"date":434,"type":47},"2026-05-29",{"date":436,"type":47},"2024-11-04",{"date":438,"type":22},"2028-05",{"name":440,"class":88},"University of Rochester",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":62,"sex":17,"minAge":448,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":67,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":53},"100514926","playing-game-to-learn-about-childrens-vaccine-project-100514926","NCT05984849","Playing Game to Learn About Children's Vaccine Project","A Pilot Randomized Controlled Study to Examine Feasibility and Preliminary Effectiveness of a Game-based Intervention in Promoting HPV Vaccination Among Vulnerable Youth to Prevent Cancers","Inclusion Criteria:\n\n* Child sample: (1) 11-14 years old, (2) speaks and reads English, (3) has never received any doses of the HPV vaccine, (4) is not currently enrolled in another project that involves HPV-related education, and (5) agrees and provides assent to participate in research activities.\n* Parent sample: (1) parent or legal guardian of the participating child, (2) speak and read English, (3) own a smartphone, (4) agree to receive email and text messages, (5) is not currently enrolled in another project that involves HPV-related education, and (6) agree and provide consent to participate in research activities.\n\nExclusion Criteria: Individuals who do not meet inclusion criteria or refuse to provide consent\u002Fassent.","11 Years","14 Years",{"count":451,"type":22},180,[69],"This proposed study aims to conduct timely research that promotes vaccine confidence and vaccination of one strongly recommended vaccine with suboptimal uptake rates: Human papillomavirus (HPV) in vulnerable and underserved youth aged 11-14.",[29,455],"Vaccine-Preventable Diseases",[457,458],"adolescent","game intervention","2026-05-18",{"date":461,"type":47},"2026-05-20",{"date":463,"type":47},"2025-10-27",{"date":465,"type":22},"2027-08-31",{"name":467,"class":88},"Michigan State University",{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":476,"minAge":477,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":67,"phases":480,"briefSummary":481,"conditions":482,"keywords":488,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":501},"100595184","screening-for-anal-cancer-in-men-who-have-sex-with-men-using-pre-exposure-prophylaxis-100595184","NCT07029152","Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis","Screening for Anal Cancer in MSM Using PrEP","SCOPE","Inclusion Criteria:\n\n* HIV-uninfected MSM (men who have sex with men) aged 35 years or older.\n* participants must have been using PrEP for at least 3 months.\n* Dutch, English or French speaking and writing\n\nExclusion Criteria:\n\n* Any intervention in the (peri-)anal region within the past 3 months\n* Enema usage within 2 h before sampling\n* Currently undergoing peri-anal topical HPV-treatment\n* HRA in the last year (anal swab or HRA prior to the last year is no exclusion)","MALE","35 Years",{"count":479,"type":22},296,[69],"This study aims to learn more about anal cancer risk in men who have sex with men (MSM) who are using Pre-Exposure Prophylaxis (PrEP) to prevent HIV. Specifically, we want to check how common High-Grade Squamous Intraepithelial Lesions (HSIL) are in this group, how well anal swabs can screen for these lesions, and how having HSIL affects their quality of life. We'll also test if DNA methylation testing can give us extra information about the lesions.\n\nThe main questions the study aims to answer are:\n\n* How common are HSIL in MSM using PrEP?\n* How accurate are anal swabs for detecting HSIL in this group?\n* How does having HSIL affect the quality of life of MSM using PrEP?\n* Can DNA methylation testing help improve our understanding of HSIL in these individuals?\n\nParticipants will:\n\n* Answer questions about their health and quality of life.\n* Have an anal smear collected for testing.\n* Undergo High-Resolution Anoscopy (HRA) to check for HSIL and get a biopsy if deemed necessary.",[483,484,485,486,29,487],"Anal Cancer","Squamous Intraepithelial Lesions","HSIL, High Grade Squamous Intraepithelial Lesions","LSIL, Low-Grade Squamous Intraepithelial Lesions","Squamous Cell Carcinoma",[489,490,491,492],"HIV prevention","men who have sex with men","pre-exposure prophylaxis (PrEP)","anal cancer","2026-04-30",{"date":495,"type":47},"2026-05-01",{"date":497,"type":47},"2025-09-23",{"date":316,"type":22},{"name":500,"class":88},"Universitair Ziekenhuis Brussel",8,{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":62,"sex":138,"minAge":425,"maxAge":426,"enrollmentInfo":509,"targetDuration":4,"studyType":67,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":518,"leadSponsor":520,"locationsCount":4},"100636230","a-bio-psycho-social-medical-model-based-study-on-adolescent-female-hpv-vaccination-behavior-and-comprehensive-intervention-100636230","NCT07562984","A Bio-Psycho-Social Medical Model-Based Study on Adolescent Female HPV Vaccination Behavior and Comprehensive Intervention","A Bio-Psycho-Social Medical Model-Based Study on Adolescent Female HPV Vaccination Behavior and Comprehensive Intervention: An International Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female, aged 9-17 years (inclusive of 9 and 17 years old).\n2. Attending pediatric \\& adolescent gynecology, adolescent health clinics, or related pediatric\u002Fchild healthcare clinics at the research centers; or attending vaccination clinics for non-HPV vaccinations (e.g., influenza, tetanus).\n3. Has not received any dose of HPV vaccine and has no definitive plan for HPV vaccination on the day of the visit (confirmed by investigator inquiry).\n4. Accompanied by at least one primary caregiver (parent or legal guardian) who can comprehend the study content and is willing to participate in shared decision-making interventions.\n5. Plans to reside mostly in the region where the research center is located for the next 12 months to facilitate follow-up.\n6. Caregiver provides written informed consent; adolescent provides informed consent\u002Fassent per local ethical requirements.\n\nExclusion Criteria:\n\n1. Previous completion of or initiation of any HPV vaccine series.\n2. History of severe allergic reaction to any HPV vaccine or its main components, or assessed by a vaccinating physician as currently unsuitable for HPV vaccination.\n3. Comorbid severe physical illness (e.g., severe cardiopulmonary disease, active malignancy) or severe mental disorder, judged by the investigator as unsuitable for participation or likely unable to complete follow-up.\n4. Participation in other clinical studies highly related to HPV vaccination behavior intervention within the past year, which may interfere with the evaluation of this study's intervention effect.\n5. Currently receiving treatment for HPV-related diseases (e.g., genital warts) where the physician considers vaccination currently inadvisable.\n6. History of autoimmune diseases or tumors.\n7. Other situations deemed by the investigator to affect study adherence or interpretation of results (e.g., families with extremely high mobility).",{"count":328,"type":22},[69],"Based on the biopsychosocial (BPS) medical model, this study focuses on HPV vaccination behavior among adolescent females. It aims to explore the influence of multidimensional factors-including biological characteristics, psychological factors, and family and social environments-on vaccination behavior, and to evaluate the effectiveness of a comprehensive HPV vaccination intervention program designed for joint participation by adolescents and their parents.\n\nThis study employs a prospective, multicenter, randomized, open-label, parallel-group design. Participants-girls and adolescents aged 9-17 who are scheduled to receive or have not yet completed HPV vaccination, along with their primary caregivers-were recruited from our hospital and collaborating pediatric\u002Fmaternal and child health institutions both domestically and internationally. Participants were randomly assigned in a 1:1 ratio to an intervention group and a control group.\n\nIn addition to routine vaccination clinic counseling, the intervention group received a comprehensive HPV vaccination intervention program based on the BPS model, including: structured health education materials (illustrated booklets\u002Fshort videos); structured communication and shared decision-making support in the clinic setting; continuous information dissemination and vaccination reminders via platforms such as WeChat; and personalized follow-up and Q\\&A sessions for families with high vaccine hesitancy; The control group received standard routine education and vaccination services.\n\nThe primary outcome was the proportion of adolescents who completed the first dose of the HPV vaccine within 3 months of enrollment; secondary outcomes included the proportion completing the full vaccination series within 6 months, changes in vaccine hesitancy levels and HPV-related knowledge, changes in anxiety\u002Fdepression levels among adolescents and caregivers, and changes in the quality of parent-child communication regarding health and vaccination as well as family decision-making patterns.\n\nThis study is expected to identify key bio-psycho-social determinants of HPV vaccination behavior among adolescent females, validate the effectiveness of the comprehensive BPS intervention in increasing vaccination rates and improving decision-making experiences and psychosocial outcomes, and provide evidence-based guidance and scalable practical pathways for pediatric and related specialty clinics to implement adolescent vaccination health promotion and family shared decision-making services.",[29,513,514],"Vaccination Hesitancy","Biopsychosocial Model","2026-04-28",{"date":495,"type":47},{"date":493,"type":22},{"date":519,"type":22},"2028-11-30",{"name":521,"class":88},"The Children's Hospital of Zhejiang University School of Medicine",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":62,"sex":138,"minAge":63,"maxAge":64,"enrollmentInfo":529,"targetDuration":4,"studyType":67,"phases":530,"briefSummary":531,"conditions":532,"keywords":535,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":53},"100619536","emergency-department-based-cervical-cancer-screening-through-self-sampling-100619536","NCT07345897","Emergency Department-based Cervical Cancer Screening Through Self-sampling","Advancing Cervical Cancer Screening Through Emergency Department-based Self-Sampling","Inclusion Criteria:\n\n* Cisgender women and transgender\u002Fnon-binary individuals with a cervix,\n* Age 30 - 65 years, and demonstrating decisional capacity to consent to participate with no known exclusion criteria present.\n\nExclusion Criteria:\n\n* Past hysterectomy with cervical removal\n* Known infection with HIV (as screening recommendations for people with HIV differ from the general population)\n* Inability to consent (e.g., lacking decisional capacity, intoxicated, or in distress)\n* Current pregnancy or in the three months after giving birth\n* Use of vaginal ovules, creams or washes, vaginal contraceptives or condoms within past 3 days\n* Sexual intercourse or transvaginal ultrasound scans or gynecological examinations within past 2 days",{"count":355,"type":22},[69],"This project will compare the uptake of cervical cancer screening through ED HPV sampling among patients presenting to the ED.",[29,533,534,73,234],"HPV Associated Cancers","HPV Cancers",[536,336,29,75],"HPV Screening","2026-04-27",{"date":539,"type":47},"2026-05-04",{"date":541,"type":47},"2026-02-13",{"date":543,"type":22},"2028-01",{"name":440,"class":88},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":138,"minAge":139,"maxAge":326,"enrollmentInfo":550,"targetDuration":4,"studyType":67,"phases":551,"briefSummary":552,"conditions":553,"keywords":554,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":53},"100622999","feasibility-study-comparing-one-vs-two-probes-for-ta-among-cervical-cancer-screen-positive-wlwh-in-c1001p-cs5-rwanda-100622999","NCT07390916","Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda",{"count":328,"type":22},[69],"Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. This is even more important at a time when Rwanda has launched a National Cervical Cancer Screening Program (NCCSP) with human papillomavirus (HPV) testing and treatment, mainly using TA with unknown outcomes. Therefore, we will conduct a feasibility study (C1001P-CS5) among 300 Rwandan WLWH to provide evidence needed to launch a future effectiveness study. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030. Rwanda hopes to achieve this goal early, in 2027 under Mission 2027.",[332,29,333],[202,336,337,338,339],"2026-04-24",{"date":557,"type":47},"2026-04-29",{"date":559,"type":22},"2026-05-31",{"date":561,"type":22},"2028-05-31",{"name":348,"class":88},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":67,"phases":572,"briefSummary":574,"conditions":575,"keywords":579,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":592},"100477019","phase-2-a-study-of-reduced-radiation-therapy-and-standard-of-care-chemotherapy-in-people-with-hpv-positive-throat-cancer-100477019","NCT05491512","A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma","Inclusion Criteria:\n\n* Pathologically (histologically or cytologically) proven diagnosis of HPV associated squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or oropharyngeal walls) from biopsy, surgical resection or excisional biopsy regardless of margin status.\n\n  1. Squamous cell carcinoma of the neck of unknown primary is allowed with excision biopsy of a lymph node (or core biopsy) or consent from the PI or co-PI\n  2. Patient must have excisional biopsy or core biopsy done in order to be on protocol\n* Subjects must have clinically or radiographically evident measurable gross disease at either the primary tumor site or nodal stations.\n* Oropharyngeal Carcinoma (AJCC, 7th ed.) without evidence of distant metastasis based on FDG PET\u002FCT.\n* CT or MRI of the neck with and without contrast Note: A CT scan of neck and\u002For a PET\u002FCT performed for the purposes of radiation planning may serve as planning tools.\n* ECOG Performance Status of 0-2 or KPS ≥ 50\n* Age ≥ 18 Patients over 70yrs will be able to enroll in Cohort B only).\n* Adequate hematologic function within 30 days prior to registration, defined as follows:\n\n  1. White Blood Count (WBC) ≥ 2 K\u002FmcL\n  2. Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3\n  3. Platelets ≥ 100,000 cells\u002Fmm3\n  4. Hemoglobin ≥ 8.0 g\u002Fdl; Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable\n* Adequate renal function within 30 days prior to registration, defined as follows:\n\n  1. Serum creatinine \\\u003C 1.5 mg\u002Fdl or creatinine clearance (CC) ≥ 50 ml\u002Fmin determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = \\[(140 - age) x (wt in kg)\\] \\[(Serum Cr mg\u002Fdl) x (72)\\] CCr female = 0.85 x (CrCl male)\n\nNote: Patients who cannot tolerate cisplatin or carboplatin\u002F5FU based on clinical judgment will receive carboplatin and paclitaxel Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel).\n\n* Adequate hepatic function within 30 days prior to registration, defined as follows:\n\n  1. Bilirubin \\\u003C 2 mg\u002Fdl\n  2. AST or ALT \\\u003C 3 x the upper limit of normal\n\nNote: Exceptions can be made with PI and\u002For Co-Pi approval for patients to enroll on trial with a higher Bilirubin level such as Gilbert's Syndrome.\n\nNote: Patients who cannot tolerate cisplatin or carboplatin\u002F5FU based on clinical judgment will receive carboplatin and paclitaxel. Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel).\n\n* Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential\n* The subject must provide study-specific informed consent prior to study entry\n* Subject able to undergo MRI scans except for major medical contraindications like presence of a pacemaker or approved by the PI or the CO-PI that the subject does not need to undergo MRI scans\n\nExclusion Criteria:\n\n* Subjects with prior head and neck radiation therapy\n* Subjects with simultaneous primary cancers outside of the oropharynx\n\n  a. Note: Exceptions can be made for patients with simultaneous primaries outside the oropharynx if determined by the PI\u002FCo-PI the patient can proceed with protocol activities.\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years to be 90% or greater\n* Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable\n* Severe, active co-morbidity defined as follows: (exceptions can be made if approved by the PI and\u002For co-PI)\n\n  1. Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  2. Transmural myocardial infarction within the last 6 months\n  3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n  4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration\n  5. Hepatic Insufficiency resulting in clinical jaundice and\u002For coagulation defects",{"count":571,"type":22},121,[573],"PHASE2","The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluorouracil (5- FU), paclitaxel and abraxane- (Albumin-bound Paclitaxel).",[29,576,577,578,172],"Throat Cancer","Oropharyngeal Carcinoma","Oropharyngeal Cancer",[580,29,576,172,577,578,581,582,583],"HPV-Positive Throat Cancer","Radiation Therapy","22-215","Memorial Sloan Kettering Cancer Center","2026-04-22",{"date":586,"type":47},"2026-04-23",{"date":588,"type":47},"2022-08-04",{"date":590,"type":22},"2027-08-04",{"name":583,"class":88},7,{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":67,"phases":603,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":109},"100585458","treatment-de-escalation-for-favorable-prognosis-human-papilloma-virus-hpv-or-p16-positive-oropharyngeal-cancer-receiving-definitive-radiotherapy-100585458","NCT06902623","Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy","A Phase II Study of Treatment De-Escalation for Favorable Prognosis, Stage I-II Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy","Lombardi197","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age on the day of signing informed consent.\n* Patients must have a diagnosis of p16+ and\u002For HPV+ squamous cell carcinoma of the oropharynx (including base of tongue, glossotonsilar sulcus, tonsil, soft palate, vallecula, and\u002For posterior oropharyngeal wall).\n* clinical stage stage I-II (T1-2 N1 M0, or T3 N0-1 M0 ) (AJCC 8th ed.) SCCA of the oropharynx that would mandate definitive chemoradiation as current standard of care when standard radiation fractionation is applied. Debulking of the disease by resecting the exophytic portion of the tumor for biopsy\u002Fsample or symptom alleviation will be permitted, as long as gross unresected tumor is left behind.\n* Subjects must agree to biopsy of areas that are FDG-avid on PET-CT scan 3-4 months after treatment.\n* Patients must have Karnofsky Performance Status (KPS) ≥ 60 within 8 weeks prior to registration\n* Patients must have had a neutrophil:lymphocyte ratio ≤ 5 within 8 weeks of registration.\n* Patient must have had a hemoglobin count ≥ 10 within 8 weeks of registration. The patient may receive transfusion to reach this goal.\n* Patients must be a current non-smoker (at least 6 months) with ≤ 15 pack-year smoking history\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Patients with gross involvement of level 4 lymph node level\n* Endophytic T3 disease, as clinically determined by the principal investigator.\n* Patients with any single lymph node \\> 4cm (multiple lymph nodes including nodal conglomerates that in sum measure \\>4cm is allowed)\n* Patients with nodal disease clinically fixed to or radiographically invading adjacent neck musculature any single lymph node \\> 4cm (multiple lymph nodes including nodal conglomerates that in sum measure \\>4cm is allowed)\n* Prior history of malignancy diagnosed within 2 years prior to registration, except for nonmelanomatous skin cancer that has completed treatment and the patient is deemed as being disease-free, or Gleason 6 prostate cancer undergoing active surveillance.\n* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.",{"count":602,"type":22},30,[69],"The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high rates of cure; this has called into question whether therapy can be decreased in intensity since both chemotherapy and radiation have long-term side effects. One approach to decrease intensity of treatment is to give radiation alone (excluding chemotherapy) and to decrease radiation therapy dose. The investigator believes that omitting chemotherapy and decreasing radiation dose both to tumor and the regions of the head and neck at highest risk of potential spread, may have no significant impact on the cancer recurring while potentially leading to fewer long-term side effects.",[606,29,607,608],"Oropharyngeal Cancers","Tonsil Cancer","Base of Tongue Cancer","2026-04-14",{"date":611,"type":47},"2026-04-17",{"date":613,"type":47},"2019-08-01",{"date":615,"type":22},"2030-12-31",{"name":617,"class":88},"Georgetown University",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":67,"phases":626,"briefSummary":627,"conditions":628,"keywords":633,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":501},"100462919","phase-2-a-study-on-using-cell-free-tumor-dna-ctdna-testing-to-decide-when-to-startroutine-treatment-in-people-with-human-papilloma-virus-hpv--associated-oropharynx-cancer-opc-100462919","NCT05307939","A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)","Phase II Trial Evaluating Selective Minimal Residual Disease Directed Adjuvant Radiation in Human Papilloma Virus Associated Oropharynx Carcinoma","Inclusion Criteria:\n\n* Age ≥ 18\n* ECOG 0-2\n* HPV-16 squamous cell carcinoma of the oropharynx or HPV-16 head and neck squamous cell carcinoma of unknown primary . HPV status must be confirmed by in-situ hybridization.\n* HPV ctDNA detectable by HPV digital PCR (Naveris assay) with a minimum of 50 copies\u002FmL pre-operatively.\n* Surgical resection of all gross disease with no gross disease visualized on post-operative imaging.\n\n  o For patients with pT0 (unknown primary) evaluation for the primary should include PET\u002FCT, direct laryngoscopy, ipsilateral tonsillectomy, and targeted biopsy. This should be followed by a neck dissection.\n* Two, undetectable (\\\u003C1 copy\u002FmL) post-operative HPV ctDNA within 2-6 weeks following surgery (blood drawn at least one week apart preferred).\n* A minimum of one of the following pathologic criteria: (Arm A)\n\n  * AJCC 7 Stage: pT0N1-N2b, pT1N1, pT2N1, or ≥pT3\n  * AJCC 7 ≥pN2\n  * Lymphovascular invasion\n  * Perineural invasion\n  * Close pathologic margin (≤ 3 mm)\n* Signed informed consent form by the participant or their legally authorized representative (LAR).\n* A minimum of one of the following pathologic criteria (Arm B):\n\n  * Microscopic positive margin\n  * Extracapsular extension\n* Signed informed consent form by the participant or their legally authorized representative (LAR).\n\nAdditional criteria for Arm B only:\n\n* Adequate hematologic function within 30 days prior to registration, defined as follows:\n\n  * White Blood Count (WBC) ≥ 2 K\u002FmcL\n  * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3\n  * Platelets ≥ 100,000 cells\u002Fmm3\n  * Hemoglobin ≥ 8.0 g\u002Fdl; Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable\n* Adequate renal function within 30 days prior to registration, defined as follows:\n\n  * Serum creatinine \\\u003C 1.5 mg\u002Fdl or creatinine clearance (CC) ≥ 50 ml\u002Fmin determined by 24-hour collection or estimated by Cockcroft-Gault formula:\n  * CCr male = \\[(140 - age) x (wt in kg)\\] divided by \\[(Serum Cr mg\u002Fdl) x (72)\\]\n  * CCr female = 0.85 x (CrCl male)\n* Adequate hepatic function within 30 days prior to registration, defined as follows:\n\n  \\- Bilirubin \\\u003C 2 mg\u002Fdl o AST or ALT \\\u003C 3 x the upper limit of normal\n* Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential\n\nExclusion Criteria:\n\n* Metastatic disease\n* Non-HPV16 genotype (i.e. HPV-18,-31, -33, -35)\n* Patients who receive surgery at outside institution. Exceptions can be made for high-volume surgical centers at the discretion of the PI\u002Fco-PI\n* Prior head and neck radiation\n* Patients without pre-operative HPV ctDNA or pre-operative HPV ctDNA ≤ 50 copies\u002FmL\n* Subjects with simultaneous primary cancers outside of the oropharynx\n\n  o Note: Exceptions can be made for patients with simultaneous primaries outside of the oropharynx if determined by the PI\u002FCo-PI, then the patient can proceed with protocol activities\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years is 90% or greater\n\n  o Note: Exceptions can be made for patients with prior invasive malignancy if determined by the PI\u002FCo-PI, then the patient can proceed with protocol activities\n* Prior systemic chemotherapy for the study cancer\n\n  o Note: prior chemotherapy for a different cancer is allowable\n* Severe, active co-morbidity defined as follows:\n\n  * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 30 days of registration\n  * Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects\n* Lack of ability to understand and willingness to sign a written informed consent and complete questionnaires.",{"count":602,"type":22},[573],"This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery.\n\nIn Arm A the researchers will see whether monitoring participants' HPV ctDNA levels can safely identify patients who do not need radiation therapy (RT) after surgery and whose RT can be delayed until their HPV ctDNA levels become detectable.\n\nIn Arm B, the researchers will see whether patients who usually need 6-6.5 weeks of CRT can be selected by HPV ctDNA to receive 3 weeks of CRT.",[29,629,630,631,632],"Oropharynx Cancer","HPV-Related Carcinoma","HPV-Related Malignancy","HPV Positive Oropharyngeal Squamous Cell Carcinoma",[634,635,636,637,583],"ctDNA","NavDx test","21-434","HPV-OPC","2026-04-10",{"date":640,"type":47},"2026-04-13",{"date":642,"type":47},"2022-03-24",{"date":644,"type":22},"2027-03-24",{"name":583,"class":88},{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":62,"sex":138,"minAge":95,"maxAge":326,"enrollmentInfo":654,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":655,"conditions":656,"keywords":664,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":676,"locationsCount":53},"100608318","impact-of-internal-menstrual-protections-on-immunity-and-vaginal-microbiota-100608318","NCT07199998","Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota","Impact of the Use of Internal Menstrual Protections on Immunity and Vaginal Microbiota","CUPS2","Inclusion Criteria:\n\n* Willingness to comply with all study procedures and availability for the duration of the study.\n* Female, aged 18 to 49 years.\n* In general good health, as determined by medical history.\n* Covered by the national health insurance system.\n* Willing to sign a written informed consent form.\n* Has already experienced menstruation prior to the start of the study.\n* No vaginal sexual intercourse within 72 hours before the study visit.\n* Has had at least 6 menstrual periods in the past 12 months.\n\nExclusion Criteria:\n\n* HIV infection.\n* Positive diagnosis for chlamydia or syphilis at screening or within 4 weeks prior to screening.\n* History of hormonal disorders or menstrual cycle irregularities.\n* Metrorrhagia.\n* Pregnancy or breastfeeding.\n* Family members or close relatives of the clinical or scientific team.\n* Treatment with any medication for chronic inflammatory disease or chronic conditions (e.g., cancer, arthritis, transplantation) within the past 12 months.\n* Participation in an ongoing clinical trial.\n* Receiving or having received antibiotic treatment within the 4 weeks prior to the study.\n* Refusal to be informed in case of detected abnormalities.\n* Indistinct use of both tampons and menstrual cups.\n* Never having had vaginal penetrative intercourse.",{"count":328,"type":22},"The availability, effectiveness, and safety of menstrual protection represent a key public health issue. However, research on women's menstrual and sexual health remains extremely limited. Whether societal or pathological, many hypotheses are emerging regarding the effects of menstrual protection products, yet little attention has been given to the products themselves, their societal role, or their physiological and pathological consequences. Internal menstrual products, such as tampons and menstrual cups, are widely used but are subject to limited regulatory oversight, and few studies have investigated their long-term effects on vaginal health.\n\nThis study aims to investigate how different types of menstrual protection influence vaginal microbiota, immune responses, and the recurrence of gynecological conditions such as bacterial vaginosis, mycosis, or dysbiosis. Biological samples (vaginal, cervical, urinary, and blood) will be collected to analyze vaginal microbiota composition and local immunity. Participants will be divided into three groups based on their main type of menstrual protection: menstrual cup users, tampon users, and external pad users. The study will compare these groups to assess potential differences in vaginal health and immune response related to menstrual product use.",[657,658,659,660,29,661,662,663],"Sexual Transmitted Disease","Vaginosis, Bacterial","Mycosis","Urogenital Disease","Dysbiosis","Toxic Shock Syndrome","Menstrual Cup",[665,661,666,667,668,669,35],"Menstrual cup","Menstrual health","Menstrual protection","Menstrual pad","Tampon","2026-04-08",{"date":672,"type":47},"2026-04-09",{"date":674,"type":47},"2026-04-07",{"date":259,"type":22},{"name":677,"class":88},"Centre National de la Recherche Scientifique, France",{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":683,"acronym":684,"eligibilityCriteria":685,"healthyVolunteers":12,"sex":138,"minAge":95,"maxAge":4,"enrollmentInfo":686,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":687,"conditions":688,"keywords":692,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":53},"100630919","hpv-after-chemoradiotherapy-100630919","NCT07493928","HPV After chemoRadioTherapy","Implementation of HPV Testing in Patients After Radiotherapy for Cervical Cancer","HART","Inclusion Criteria:\n\n* Patient indicated for primary RT for cervical cancer\n* FIGO stage IB - IVA\n* Signed informed consent\n* Age ≥ 18 years\n* Administration of RT with curative intent\n\nExclusion Criteria:\n\n* Clinical stage FIGO IA\n* Clinical stage FIGO IVB\n* History of radiotherapy in the pelvis\n* Hysterectomy performed before the start of radiotherapy (adjuvant RT)\n* History of HPV-associated malignancy in personal history\n* HIV or other significant immunodeficiency",{"count":167,"type":22},"The HART (HPV After chemoRadiotherapy) study is a prospective multicenter observational trial designed to evaluate the clinical utility of HPV testing in the follow-up of patients treated with definitive chemoradiotherapy (CRT) for cervical cancer. Current surveillance after CRT relies mainly on clinical examination and imaging, while the role of HPV-based molecular monitoring remains insufficiently defined. The study plans to enroll 120 patients with FIGO stage IB-IVA cervical cancer treated with primary radiotherapy with curative intent. HPV detection will be performed using two complementary approaches: PCR-based detection of HPV DNA from a cervical swab and analysis of circulating HPV tumor DNA (ctDNA) in peripheral blood. Samples will be collected before treatment and during follow-up at 3, 12, and 24 months after completion of CRT. The primary objective is to determine the sensitivity of these methods for detecting disease recurrence during a two-year follow-up period. Secondary objectives include evaluation of HPV clearance after treatment, comparison of HPV genotypes before and after therapy in cases of persistence, and comparison of the diagnostic performance of cervical HPV testing and ctDNA detection. The study aims to generate evidence supporting the integration of HPV-based molecular monitoring into routine follow-up, potentially enabling earlier detection of recurrence and more individualized surveillance strategies for patients after CRT for cervical cancer.",[689,690,691,29],"Cervical Cancer Recurrent","Radiotherapy","Cell Free DNA",[693,694,695],"cervical cancer","cfDNA","radiotherapy","2026-03-20",{"date":698,"type":47},"2026-03-25",{"date":700,"type":47},"2026-02-01",{"date":702,"type":22},"2030-02-01",{"name":704,"class":88},"General University Hospital, Prague"]